ROARABLE // PRO
[FREE TERMINAL]
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

KYMR // Kymera Therapeutics Inc.

DES <GO> NASDAQ CIK 0001815442 ↗
Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$122.60 ▲ +0.09 (+0.07%)
MKT CAP: $10.19B • VOL: 1.05M
KYMR // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
PRIOR: RQD 57/100 [D+] (+0 PT) • UNCHANGED
ROARABLE D+
RQD CONFIDENCE
57 / 100 +0D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Sell — Weak Fundamentals / Trim
01 MASSIVE / SEC XBRL
Forensic Fundamentals
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
02 OPRA GEX + SEC 13F
Whale & Options Flow
10 / 20
NEUTRAL
NET GEX +0% • CALL SWEEP 52% • P/C 0.84
03 SEC FORM 4 (90D)
Insider Conviction
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
04 FRED 90D r-MATRIX
Macro Regime Fit
17 / 20
STRONG
TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00
05 10-K REDLINE AUDIT
Forensic 10-K Risk
13 / 20
SOLID
20 BASE - 7 DEDUCT • 0 CRIT / 0 MED • STABLE
ALERT

Why did KYMR's Forensic Fundamentals & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever KYMR is Upgraded or Downgraded.
SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON KYMR)
ALL MARKET ANOMALIES <SIG>
▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS
SEVERITY: 84/100 Z-SCORE: +2.50σ

KYMR Accounting Gap: Net Income (+39.1%) Outpaced OCF (-19.7%) With +48.5% Working-Capital Build

CASH CONVERSION GAP
+58.8% (NI vs OCF)
RECEIVABLES / WC BLOAT
+48.5% VS REV
60D C-SUITE FORM 4 SALES
0 OPEN-MKT DUMPS
[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]
SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Kymera Therapeutics Inc. (KYMR) exposes a +58.8% Cash Conversion Gap as YoY Net Income growth (+39.1%) diverged from Operating Cash Flow growth (-19.7%). Non-cash current assets and receivables expanded +48.5% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

KYMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +56.20%▲ RESISTANCE BREAKOUT
2026-10-30O $122.6H $127.3L $117.3C $126.6VOL 1.59M
RES: $125.4SUP: $102.6SMA50: $114.9SMA200: $96.42
$134.5$116.2$97.90$79.63$61.35RES $125.4SUP $102.6$126.62026-04-302026-06-152026-07-312026-09-162026-10-30
KYMR // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
UNDERWEIGHT CONVICTION: 28/100
BEAR 0
100 BULL

Kymera Therapeutics Inc. (KYMR) exhibits 0.0% gross margins and -21.4% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 32.7x enterprise multiple and 6.7% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained 0.0% gross profitability converts into -60.0% operating margin and -21.4% ROIC, outpacing sector cost of capital.

ROIC: -21.4% // GM: 0.0%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of -16.7% paired with -2.30% free cash flow yield supports self-funded R&D and capital return.

REV YOY: -16.7% // FCF YLD: -2.30%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 26.00 and Piotroski F-Score of 4/9 indicate low near-term refinancing stress.

ALTMAN Z: 26.00 // F-SCORE: 4/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 32.7x trailing P/E (30.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 32.7x // EV/EBITDA: —
02. Options Skew & Event Volatility Risk

Options market prices a ±6.7% implied move with a 0.84 put/call ratio around $120.00 max pain.

IMPL MOVE: ±6.7% // P/C: 0.84
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 68.0% net margins.

NET MARGIN: 68.0% // D/E: 0.04x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 30.4x forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 0.95).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E 32.7x
FORWARD P/E 30.4x
EV / EBITDA —
FCF YIELD -2.30%
GROSS MARGIN 0.0%
OPERATING MARGIN -60.0%
NET MARGIN 68.0%
ROIC % -21.4%
REV GROWTH YOY -16.7%
DILUTED EPS TTM $3.74
DEBT / EQUITY 0.04x
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 69.3
5Y EQUITY BETA 0.95
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // KYMRPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $112.18
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KYMR & activate live FRED threshold breach alerts.
HEAD-TO-HEAD PEER COMPARISONS COMP <GO>
KYMR VS LLY
MARGINS ROIC VALUATION
KYMR VS JNJ
MARGINS ROIC VALUATION
KYMR VS ABBV
MARGINS ROIC VALUATION
KYMR VS UNH
MARGINS ROIC VALUATION